Yaz Helpline launched for Female Victims of Yaz Birth Control Pills
Yaz Yasmin Helpline Speak to a female Social Worker and be connected to a yaz lawyer
/EINPresswire.com/ FDA Warnings Yaz causes blood clots Yaz Helpline for Women's Health Lawyers Yaz Helpline The Yaz, Yasmine,Ocella Women's Helpline is based on an FDA Warning for the drugs YAZ,Yasmin and Ocella. Class action lawsuits for Yaz,Yasmin and ocella are currently being filed. If you have experienced complications with Yaz,Yasmin or ocella,call the a Yaz, Ocella,Yaz Lawyer Helpline Attorney today. The helpline is here for you 24/7 877 522 2123 You will speak to a medical social worker.
The Federal/State Yaz, Yasmin, Ocella Birth Control Lawsuits are being filed by the lawyers of classactionlawyernetwork.com. The Yaz, Yasmine,Ocella Helpline is here to answer your questions and connect you with a YAZ, Yasmin or Ocella, Yaz lawyer.Referencing the New York Times," Yaz has been one of the top-selling birth control pills in the U.S and Canada., with nearly 20 percent of the market. In 2008, more than $600 million dollars' worth of Yaz was sold in the U.S. However, the television commercials advertising Yaz were of concern to the FDA and Attorneys General because they implied that Yaz could be used to treat or cure symptoms for which it was not FDA-approved, such as:
Keeping a woman's mild acne at bay
Relieving symptoms of PMS (premenstrual syndrome):
irritability
increased appetite
moodiness
fatigue
headaches
bloating
muscle aches
Bayer agreed to make new commercials and print advertisements that did not promise more for Yaz than had been approved by the FDA, and that did not minimize the risks of Yaz birth control pills, which are many. Yaz is FDA-approved only for:
preventing pregnancy
treating the symptoms of PMDD (premenstrual dysphoric disorder) in women who are using Yaz as their contraceptive
treating moderate acne vulgaris in women who are using Yaz to prevent pregnancy
Safety Announcement
[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. FDA has completed its review of the two 2011 studies that evaluated the risk of blood clots for women who use drospirenone-containing birth control pills, previously mentioned in FDA's Drug Safety Communication issued on May 31, 2011. FDA is continuing its review of a separate FDA-funded study that evaluated the risk of blood clots in users of several different hormonal birth control products (contraceptives). Preliminary results of the FDA-funded study suggest an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives.
Given the conflicting nature of the findings from six published studies evaluating this risk, as well as the preliminary data from the FDA-funded study (See Data Summary), FDA has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8, 2011 to discuss the risks and benefits and specifically the risk of blood clots of drospirenone-containing birth control pills.
Patients should talk to their healthcare professional about their risk for blood clots before deciding which birth control pill to use. Known risk factors that increase the risk of a blood clot include smoking, being overweight (obesity), and family history of blood clots, in addition to other factors that contraindicate use of birth control pills.
Women currently taking a drospirenone-containing birth control pill should be informed of the potential risk for blood clots. FDA previously communicated preliminary information about these concerns to the public on May 31, 2011 .
FDA has prepared a list of questions and answers to provide an overview of this potential safety issue. FDA will continue to communicate any new information to the public as it becomes available
Health Canada is currently reviewing the safety of Bayer Pharmaceutical's birth control pills, Yaz and Yasmin, in an effort to determine if women who use these drugs are at an increased risk of developing life-threatening blood clots over women using different brands of birth control.
The review was prompted by two new studies recently published in the British Medical Journal, which concluded that women ages 15-44 taking birth control pills containing the synthetic progestin, drospirenone, are more likely to develop blood clots deep in the veins of the leg (venous thromboembolism), than women using birth control pills containing the common progestin levonorgestrel. The studies reported that the risk of developing blood clots for women taking the drospirenone-containing pills may be two to three times greater than those who take other pills. Yaz is one of these drugs.
Yaz side effects include:
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Blood clots
• Stroke
• Heart attack
• Gallbladder problems
• Pancreatis
List of Drugs
Approved Oral Contraceptives containing Drospirenone are included in the FDA warning
Recent warnings have linked various birth control drugs and devices to serious injuries and even death:
If you or a loved one has suffered from any of the harmful side effects of Yaz,Yasmin or Ocella such as blood clots, stroke or heart attack you may be entitled to file a Yaz,Yasmin,Ocella lawsuit against the manufacturer. A Yaz, Yasmin Helpline Attorney for Women's health with experience in birth control drug lawsuits can help evaluate your claim. Many women around the United States have suffered from life-threatening Yaz,Ocella and Yasmin birth control side effects. The manufacturer can be held liable.
The Woman's Yaz Helpline is her for women suffering from Yasmin and Yaz side effects 1 877 522-2123
/EINPresswire.com/ FDA Warnings Yaz causes blood clots Yaz Helpline for Women's Health Lawyers Yaz Helpline The Yaz, Yasmine,Ocella Women's Helpline is based on an FDA Warning for the drugs YAZ,Yasmin and Ocella. Class action lawsuits for Yaz,Yasmin and ocella are currently being filed. If you have experienced complications with Yaz,Yasmin or ocella,call the a Yaz, Ocella,Yaz Lawyer Helpline Attorney today. The helpline is here for you 24/7 877 522 2123 You will speak to a medical social worker.
The Federal/State Yaz, Yasmin, Ocella Birth Control Lawsuits are being filed by the lawyers of classactionlawyernetwork.com. The Yaz, Yasmine,Ocella Helpline is here to answer your questions and connect you with a YAZ, Yasmin or Ocella, Yaz lawyer.Referencing the New York Times," Yaz has been one of the top-selling birth control pills in the U.S and Canada., with nearly 20 percent of the market. In 2008, more than $600 million dollars' worth of Yaz was sold in the U.S. However, the television commercials advertising Yaz were of concern to the FDA and Attorneys General because they implied that Yaz could be used to treat or cure symptoms for which it was not FDA-approved, such as:
Keeping a woman's mild acne at bay
Relieving symptoms of PMS (premenstrual syndrome):
irritability
increased appetite
moodiness
fatigue
headaches
bloating
muscle aches
Bayer agreed to make new commercials and print advertisements that did not promise more for Yaz than had been approved by the FDA, and that did not minimize the risks of Yaz birth control pills, which are many. Yaz is FDA-approved only for:
preventing pregnancy
treating the symptoms of PMDD (premenstrual dysphoric disorder) in women who are using Yaz as their contraceptive
treating moderate acne vulgaris in women who are using Yaz to prevent pregnancy
Safety Announcement
[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. FDA has completed its review of the two 2011 studies that evaluated the risk of blood clots for women who use drospirenone-containing birth control pills, previously mentioned in FDA's Drug Safety Communication issued on May 31, 2011. FDA is continuing its review of a separate FDA-funded study that evaluated the risk of blood clots in users of several different hormonal birth control products (contraceptives). Preliminary results of the FDA-funded study suggest an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives.
Given the conflicting nature of the findings from six published studies evaluating this risk, as well as the preliminary data from the FDA-funded study (See Data Summary), FDA has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8, 2011 to discuss the risks and benefits and specifically the risk of blood clots of drospirenone-containing birth control pills.
Patients should talk to their healthcare professional about their risk for blood clots before deciding which birth control pill to use. Known risk factors that increase the risk of a blood clot include smoking, being overweight (obesity), and family history of blood clots, in addition to other factors that contraindicate use of birth control pills.
Women currently taking a drospirenone-containing birth control pill should be informed of the potential risk for blood clots. FDA previously communicated preliminary information about these concerns to the public on May 31, 2011 .
FDA has prepared a list of questions and answers to provide an overview of this potential safety issue. FDA will continue to communicate any new information to the public as it becomes available
Health Canada is currently reviewing the safety of Bayer Pharmaceutical's birth control pills, Yaz and Yasmin, in an effort to determine if women who use these drugs are at an increased risk of developing life-threatening blood clots over women using different brands of birth control.
The review was prompted by two new studies recently published in the British Medical Journal, which concluded that women ages 15-44 taking birth control pills containing the synthetic progestin, drospirenone, are more likely to develop blood clots deep in the veins of the leg (venous thromboembolism), than women using birth control pills containing the common progestin levonorgestrel. The studies reported that the risk of developing blood clots for women taking the drospirenone-containing pills may be two to three times greater than those who take other pills. Yaz is one of these drugs.
Yaz side effects include:
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Blood clots
• Stroke
• Heart attack
• Gallbladder problems
• Pancreatis
List of Drugs
Approved Oral Contraceptives containing Drospirenone are included in the FDA warning
Recent warnings have linked various birth control drugs and devices to serious injuries and even death:
If you or a loved one has suffered from any of the harmful side effects of Yaz,Yasmin or Ocella such as blood clots, stroke or heart attack you may be entitled to file a Yaz,Yasmin,Ocella lawsuit against the manufacturer. A Yaz, Yasmin Helpline Attorney for Women's health with experience in birth control drug lawsuits can help evaluate your claim. Many women around the United States have suffered from life-threatening Yaz,Ocella and Yasmin birth control side effects. The manufacturer can be held liable.
The Woman's Yaz Helpline is her for women suffering from Yasmin and Yaz side effects 1 877 522-2123